|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Kalydeco
gptkb:Orkambi
gptkb:Trikafta
|
|
gptkbp:activities
|
potentiator of CFTR
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
January 31, 2012
|
|
gptkbp:brand
|
gptkb:Kalydeco
|
|
gptkbp:can_be_used_with
|
gptkb:lumacaftor
gptkb:tezacaftor
|
|
gptkbp:clinical_trial
|
Phase 3
long-term treatment
|
|
gptkbp:contraindication
|
hypersensitivity to ivacaftor
|
|
gptkbp:discovered_by
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:dosage_form
|
tablets
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
film-coated tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
ivacaftor
|
|
gptkbp:indication
|
G551 D mutation in CFTR gene
|
|
gptkbp:ingredients
|
C24 H26 Cl F3 N2 O
|
|
gptkbp:interacts_with
|
strong CY P3 A inducers
strong CY P3 A inhibitors
|
|
gptkbp:invention
|
2027
patented
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
gptkb:cystic_fibrosis
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
CY P3 A4
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:population
|
adults
children over 2 years
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_access_to
|
patient assistance program
|
|
gptkbp:provides_information_on
|
recommended for specific mutations
|
|
gptkbp:research
|
combination therapies
long-term safety
efficacy in children
real-world effectiveness
|
|
gptkbp:research_areas
|
cystic fibrosis therapies
|
|
gptkbp:safety_features
|
liver function tests
respiratory events
|
|
gptkbp:scholarships
|
gptkb:Educational_Institution
gptkb:charity
support groups
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
rash
elevated liver enzymes
upper respiratory tract infection
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
CFTR protein
|